We proved that combined inhibition of EphA2, an ovarian cancer oncogene, with EphA2 siRNA and miR‐520d‐3p mimic exhibits synergistic effects (Nishimura et al., 2013). Here, EPHA2 is linked to ovarian carcinoma.